Kintara Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Good morning, everyone. It is my pleasure to welcome Kintara Therapeutics, the next presenting company. Oncology-focused company developing drugs for both GBM and metastatic breast cancer, if I'm remembering it correctly. Presenting for the company is Rob Hoffman, President, and CEO.
Thanks, [Brent]. Pleasure to be here at JMP and looking forward to telling you why I am really excited about the future at Kintara. Before I begin, I would like to point out that I'll be making numerous forward-looking statements during the presentation. Actual results may differ. So just look at our risk factors on file with the SEC or on our website.
Before I get started, I've been getting this question quite a bit, why did I come out of retirement.
So, a little bit about my background. I spent 17 years at Arena Pharmaceuticals. Took the company public in 2000; joined in '97 part of the start-up management team; raised $1.2 billion, $1.3 billion; spent $1.4
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
